Drugs / BMS-986094
BMS-986094
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01250366 | Oct 2010 → Mar 2011 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01159808 | May → Aug 2010 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01471717 | Oct → Nov 2011 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01471704 | Oct → Nov 2011 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01445795 | Sep 2011 → May 2012 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01629732 | Mar 2013 → Feb 2014 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 2 | NCT01425970 | May 2012 → Aug 2013 | hepatitis C virus infection | Bristol-Myers Squibb | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2012-08-23 | Bristol-Myers Squibb | Regulatory Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C bms.com ↗
The U.S. Food and Drug Administration (FDA) subsequently placed the compound on clinical hold. |
| 2012-08-01 | Bristol-Myers Squibb | Results Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C bms.com ↗
This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-08-23 | Bristol-Myers Squibb | Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C bms.com ↗ |
| 2012-08-01 | Bristol-Myers Squibb | Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C bms.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986094 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01629732 ↗ |
| Known as | INX-08189 | “BMS-986094 (INX-08189)” NCT01629732 ↗ |
| Known as | INX-089 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1209734 ↗ |
| Known as | INX-189 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1209734 ↗ |
| Modality | Small molecule | — CHEMBL1209734 ↗ |
| Route | Oral | “oral administration” NCT01159808 ↗ |